8-K
filed November 15, 2023, 6:59 PM ET
CIK 0001971543
M&A
confidence high
sentiment positive
materiality 0.75
Mural Oncology plc: M&A transaction — Mural Oncology spins off from Alkermes with $275M funding; nemvaleukin trials readout in 1Q2025
Mural Oncology plc
- Spin-off completed Nov 15, 2023; Mural shares trade on Nasdaq under 'MURA' starting Nov 16.
- $275M committed funding provides cash runway projected into 4Q 2025.
- Lead candidate nemvaleukin in two potentially registrational trials; top-line data expected 1Q 2025.
- Preclinical IL-18 and IL-12 programs; development candidate nominations planned in 2024.
- Executive team includes CEO Caroline Loew, CFO Adam Cutler, CMO Vicki Goodman; board chaired by Scott Jackson.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Caroline Loew, Ph.D. was elected as Chief Executive Officer at Mural Oncology plc.
- Action
- elected
- Role
- Chief Executive Officer
Exact text from the filing
In connection with the Separation, the following individuals were elected to the positions set forth in the table below: Name Position Caroline Loew, Ph.D. Chief Executive Officer
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Caroline Loew, Ph.D. resigned as Principal Financial Officer and Principal Accounting Officer at Mural Oncology plc.
- Action
- resigned
- Role
- Principal Financial Officer and Principal Accounting Officer
Exact text from the filing
In connection with the Separation, Dr. Caroline Loew resigned as Principal Financial Officer and Principal Accounting Officer, effective as of November 15, 2023.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Adam Cutler was appointed as Principal Financial Officer and Principal Accounting Officer at Mural Oncology plc.
- Action
- appointed
- Role
- Principal Financial Officer and Principal Accounting Officer
Exact text from the filing
In connection with the Separation, Adam Cutler was appointed as Principal Financial Officer and Principal Accounting Officer, effective as of November 15, 2023.
View on SEC.gov
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
Mural Oncology plc: Amended and restated Memorandum and Articles of Association (Constitution) (effective 2023-11-15).
- Change
- charter amendment
- Effective
- 2023-11-15
Exact text from the filing
The Memorandum and Articles of Association of Mural (the “Constitution”) was amended and restated, effective November 15, 2023.
View on SEC.gov
M&A Transactions
SEC 8-K Item 2.01/5.01
confidence 0.9
Mural Oncology plc completed a disposition involving Alkermes plc (closed 2023-11-15).
- Action
- disposition
- Counterparty
- Alkermes plc
- Closing
- 2023-11-15
Exact text from the filing
On November 15, 2023, Alkermes plc (“Alkermes”) completed the previously announced separation (the “Separation”) of its oncology business into Mural Oncology plc (“Mural”), a new, independent, publicly-traded company.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Mural Oncology plc entered into Lease Assumption Agreement with Alkermes Subsidiary (effective 2023-11-13).
- Action
- entry
- Agreement
- lease
- Counterparty
- Alkermes Subsidiary
- Effective
- 2023-11-13
Exact text from the filing
Alkermes Subsidiary entered into an assignment and assumption of lease agreement (the "Lease Assumption Agreement") with Mural Subsidiary, dated as of November 13, 2023
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.